These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30508783)

  • 1. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
    Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
    Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
    Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
    J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
    Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study.
    Li WY; Wei HY; Sun YZ; Zhou H; Ma Y; Wang RL
    J Cell Biochem; 2018 Dec; 119(12):9941-9956. PubMed ID: 30129165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation.
    Li WY; Ma Y; Li HX; Lu XH; Du S; Ma YC; Zhou L; Wang RL
    Bioorg Chem; 2020 Dec; 105():104391. PubMed ID: 33113413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
    Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
    J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study.
    Sun YZ; Chen XB; Wang RR; Li WY; Ma Y
    J Cell Biochem; 2019 Apr; 120(4):5949-5961. PubMed ID: 30304563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
    Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
    J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
    Wang Q; Zhao WC; Fu XQ; Zheng QC
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
    He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
    Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
    Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
    Front Immunol; 2022; 13():958616. PubMed ID: 35983034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
    J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
    Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
    Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
    Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
    Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
    Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C
    J Biol Chem; 2021; 296():100538. PubMed ID: 33722610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML.
    Zhao Y; He C; Zhang D; Guo Y; Peng Z; Yu L; Li N; Chen C; Zhao ZJ; Chen Y
    Exp Hematol Oncol; 2023 Feb; 12(1):20. PubMed ID: 36805832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
    Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
    J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
    Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.